WHO Endorses Dual-Stain Cytology Testing
Roche is excited to share that the World Health Organization (WHO) has officially adopted dual-stain cytology testing, specifically the CINtec PLUS Cytology test, in its updated guidelines for cervical cancer prevention. This important recognition highlights Roche's commitment to improving cervical cancer solutions and the overall quality of patient care.
Importance of Dual-Stain Cytology Testing
The CINtec PLUS Cytology test is the only dual-stain test approved by the FDA and carries CE certification. It's designed for individuals who have tested positive for human papillomavirus (HPV). By employing dual-stain biomarkers, this cutting-edge test helps identify the risks of cervical precancer and cancer. As a result, it can significantly reduce the number of unnecessary colposcopies, paving the way for timely interventions for those at higher risk.
Working with Leading Organizations
This recognition from the WHO coincides with the updated guidelines from the American Society for Colposcopy and Cervical Pathology (ASCCP), which now includes dual-stain testing for patients who are HPV-positive. Such endorsements showcase a collaborative effort within the healthcare community to improve the detection and treatment of cervical cancer.
If a patient's dual-stain test comes back positive, it signifies a greater likelihood of existing precancer or cancer, leading clinicians to suggest immediate colposcopy. On the other hand, a negative result indicates a lower risk of precancer, allowing for follow-up testing later to monitor the infection's progression or resolution.
Enhancing Patient Management
According to Matt Sause, CEO of Roche Diagnostics, “Including dual-stain cytology in WHO guidelines further affirms the utility of our CINtec PLUS Cytology test in identifying individuals at heightened risk for cervical cancer.” This test concurrently detects two biomarkers—p16 and Ki-67—within a single cell, which are critical indicators of potential cancer transformation. By identifying at-risk individuals, not only is patient management streamlined, but healthcare resources could be conserved by possibly reducing follow-up visit frequencies.
A Major Step Toward Cervical Cancer Elimination
The revised WHO guidelines not only enhance efforts to prevent cervical cancer but also act as a driving force in the global initiative to eradicate cervical cancer as a public health issue. Roche's extensive portfolio, including the cobas HPV test, has gained WHO prequalification, ensuring worldwide access and standardization in cervical cancer screening practices.
Discovering Roche’s Cervical Cancer Portfolio
Cervical cancer remains a prominent health concern globally, with HPV responsible for over 95% of cases. Roche's goal is clear: through innovative tests like CINtec PLUS Cytology and the cobas HPV test—which covers high-risk HPV types—we aim to significantly lower the rates of cervical cancer.
The cobas HPV test, a central component of Roche’s cervical cancer strategy, operates on fully automated systems that deliver up to 96 results within just three hours. This quick turnaround is essential for providing timely feedback and interventions. Additionally, tools like CINtec PLUS Histology are available for healthcare professionals, focusing on confirming precancerous lesions.
Roche's Commitment to Diversity and Inclusion in Healthcare
Roche's clinical trials, such as the IMPACT trial, involve diverse patient populations to ensure inclusivity in results. Understanding different demographic specifics, including the higher incidence rates of HPV among certain ethnic groups, is crucial in finding effective cervical cancer solutions.
Future Directions in Cervical Cancer Prevention
Roche is also testing the navify® Cervical Screening software to improve adherence to clinical guidelines, optimizing healthcare resources while ensuring the best outcomes for patients. By emphasizing cervical cancer prevention through education and advanced testing, Roche is striving to make a substantial contribution to global health.
About Roche
Established in 1896 in Basel, Switzerland, Roche has developed into a premier biotechnology company focused on innovative diagnostic solutions and treatments. Sustainability is a core principle at Roche, as we aim to achieve net-zero emissions by 2045.
Genentech, a wholly owned subsidiary of the Roche Group located in the United States, in conjunction with our partnership with Chugai Pharmaceutical in Japan, further strengthens our commitment to global healthcare.
Frequently Asked Questions
What is the CINtec PLUS Cytology test?
The CINtec PLUS Cytology test, created by Roche, is a dual-stain test aimed at identifying individuals who are high-risk HPV-positive and at risk for developing cervical precancer or cancer.
How does the dual-stain test impact cervical cancer screening?
This test provides healthcare practitioners with a way to triage HPV-positive results, decreasing unnecessary colposcopies for patients at lower risk; it ultimately helps streamline patient care.
Why is the WHO’s endorsement important?
The WHO's endorsement lends credibility to the CINtec PLUS Cytology test's effectiveness and promotes its widespread use in strategies for preventing cervical cancer.
What does Roche include in its cervical cancer portfolio?
Roche’s cervical cancer offerings feature the CINtec PLUS Cytology test and the cobas HPV test, working together to enhance early detection and management of cervical cancer.
How does Roche ensure diversity in its clinical trials?
Roche strives to involve a varied patient population in its trials to ensure that its products and solutions are effective for individuals from different demographic backgrounds.
